Report: Moderna COVID-19 Vaccine Trial Delayed

The world can't wait for a COVID-19 vaccine, but the world might just have to wait a touch longer. According to a report published Thursday on biotech industry news site STAT, citing investigators presumably involved in the research, a phase 3 clinical trial of Moderna's (NASDAQ: MRNA) mRNA-1273 has been delayed. This delay, the length of which was not specified, is due to the fact that Moderna is modifying the protocol of the research.

mRNA-1273 is one of the leading vaccine candidates for COVID-19, and it has vaulted Moderna to the top ranks of coronavirus stocks. Many pundits and infectious disease experts consider mRNA-1273 to be No. 1 among the vaccines currently being developed. The phase 3 trial, involving around 30,000 patients, was to begin this month.

Image source: Getty Images.

Continue reading

Source Fool.com